Trexquant Investment LP Grows Stock Holdings in Insulet Corporation $PODD

Key Points

• Trexquant Investment LP increased its holdings in Insulet Corporation by 3.7%, acquiring an additional 2,540 shares, bringing its total ownership to approximately $18.5 million.
• Insulet reported an earnings per share (EPS) of $1.17 for the last quarter, significantly surpassing the consensus estimate of $0.92 and showing a year-over-year revenue growth of 32.9%.
• Brokerages have shown optimism by upgrading Insulet's stock ratings, with Wolfe Research setting a target price of $350.00 after moving from a "peer perform" to an "outperform" rating.

Trexquant Investment LP boosted its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 3.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 70,585 shares of the medical instruments supplier's stock after acquiring an additional 2,540 shares during the period. Trexquant Investment LP owned 0.10% of Insulet worth $18,536,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new stake in Insulet in the 1st quarter worth $26,000. Larson Financial Group LLC grew its holdings in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares during the last quarter. SouthState Corp grew its holdings in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Insulet in the 4th quarter worth $42,000. Finally, Ramirez Asset Management Inc. bought a new stake in Insulet in the 1st quarter worth $53,000.

Insulet Stock Up 0.7%

NASDAQ:PODD traded up $2.28 during mid-day trading on Friday, hitting $339.88. 515,158 shares of the company's stock were exchanged, compared to its average volume of 702,791. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a market cap of $23.92 billion, a PE ratio of 103.31, a P/E/G ratio of 2.85 and a beta of 1.36. Insulet Corporation has a one year low of $199.68 and a one year high of $341.14. The business has a fifty day moving average price of $304.04 and a 200 day moving average price of $287.71.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business's revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PODD shares. Royal Bank Of Canada raised their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. The Goldman Sachs Group initiated coverage on shares of Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 target price on the stock. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a research note on Tuesday, May 13th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and an average price target of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.